Rapport Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022
Net Income	-34.79	-10.65
Depreciation & Amortization	0.32	0.02
Share-Based Compensation	3.53	0.56
Other Operating Activities	3.76	6.84
Operating Cash Flow	-27.18	-3.24
Capital Expenditures	-1.64	-0.28
Acquisitions	0	-5
Change in Investments	-77.22	0
Investing Cash Flow	-78.86	-5.28
Share Issuance / Repurchase	0.05	0.03
Debt Issued / Paid	0	7.9
Other Financing Activities	145.09	31.76
Financing Cash Flow	145.14	39.69
Net Cash Flow	39.1	31.16
Free Cash Flow	-28.82	-3.53
Free Cash Flow Per Share	-2.23	-0.53

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).